PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1782938
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1782938
Global Myomectomy Market to Reach US$1.2 Billion by 2030
The global market for Myomectomy estimated at US$779.3 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 8.0% over the analysis period 2024-2030. Laparoscopic Power Morcellators, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$464.9 Million by the end of the analysis period. Growth in the Harmonic Scalpel segment is estimated at 8.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$212.3 Million While China is Forecast to Grow at 12.6% CAGR
The Myomectomy market in the U.S. is estimated at US$212.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$266.5 Million by the year 2030 trailing a CAGR of 12.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.
Global Myomectomy Market - Key Trends & Drivers Summarized
Myomectomy, a surgical procedure for the removal of uterine fibroids while preserving the uterus, is increasingly being recognized as a preferred treatment option for women seeking fertility preservation. The rising prevalence of uterine fibroids, which affect millions of women globally, has led to increased awareness and diagnosis, boosting the demand for effective treatment solutions. Unlike hysterectomy, which involves the complete removal of the uterus, myomectomy offers women the ability to retain reproductive function, making it an attractive choice among younger patients. Technological advancements in minimally invasive surgical techniques, such as laparoscopic and robotic-assisted myomectomy, have further improved patient outcomes, reducing recovery time, surgical risks, and hospital stays. Additionally, a growing emphasis on women’s reproductive health and the increasing availability of non-invasive diagnostic methods, such as ultrasound and MRI, are contributing to early detection and treatment planning. With the rising trend toward patient-centric care, healthcare providers are prioritizing myomectomy as a safer and more effective alternative to traditional surgical procedures.
The evolution of surgical technology has significantly enhanced the efficiency and safety of myomectomy procedures, making them more accessible to a larger patient population. The introduction of robotic-assisted surgery has revolutionized myomectomy by offering superior precision, minimal blood loss, and faster recovery times compared to conventional open surgery. Innovations in laparoscopic instruments and energy-based surgical devices, such as harmonic scalpels and radiofrequency ablation, have further improved the accuracy and success rates of fibroid removal. Additionally, the integration of artificial intelligence (AI) and real-time imaging systems is enabling surgeons to perform highly precise procedures with enhanced visualization and intraoperative decision-making capabilities. The shift toward outpatient and same-day surgery centers is also facilitating greater adoption of minimally invasive myomectomy, reducing healthcare costs and increasing convenience for patients. As advancements in surgical robotics, AI-assisted diagnostics, and personalized treatment planning continue to emerge, the myomectomy market is poised for substantial growth, offering patients safer and more effective treatment options.
The myomectomy market is being shaped by evolving treatment approaches and patient preferences, driving new trends in fibroid management. One notable trend is the increasing demand for uterus-sparing procedures, reflecting a shift in women’s healthcare priorities toward fertility preservation and improved quality of life. The adoption of integrative and multimodal treatment strategies, including hormonal therapy and non-surgical interventions like high-intensity focused ultrasound (HIFU), is also gaining traction as complementary approaches to myomectomy. Additionally, advancements in pharmacological treatments, such as GnRH antagonists and selective progesterone receptor modulators (SPRMs), are helping shrink fibroids preoperatively, making surgery less invasive and reducing potential complications. The rising role of telemedicine and digital health platforms is further enhancing patient engagement, allowing for remote consultations, pre-surgical assessments, and post-operative care management. Furthermore, an increasing focus on health equity and awareness campaigns is leading to better access to fibroid treatment options for underserved populations. As patient education and non-invasive alternatives continue to expand, myomectomy is expected to remain a cornerstone in fibroid treatment strategies.
The growth in the myomectomy market is driven by several factors, including rising fibroid incidence, advancements in minimally invasive surgical techniques, and increasing patient awareness about fertility-preserving treatment options. The expanding prevalence of uterine fibroids among women of reproductive age has heightened the demand for effective and uterus-sparing interventions. Technological innovations, such as robotic-assisted surgery, AI-powered diagnostics, and improved surgical instrumentation, are enabling safer and more precise procedures, contributing to market expansion. The growing number of ambulatory surgical centers (ASCs) offering outpatient myomectomy services is also making the procedure more accessible and cost-effective for patients. Additionally, supportive healthcare policies and increasing insurance coverage for fibroid treatments are encouraging more women to opt for myomectomy over hysterectomy. Pharmaceutical advancements, particularly in preoperative fibroid management, are further enhancing surgical outcomes and expanding treatment possibilities. As the focus on women’s health and reproductive care intensifies, the myomectomy market is expected to witness continued growth, solidifying its role as a leading option for fibroid management worldwide.
SCOPE OF STUDY:
The report analyzes the Myomectomy market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product Type (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer, Other Product Types); Procedure Type (Abdominal Myomectomy, Hysteroscopic Myomectomy, Laparoscopic Myomectomy); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 43 Featured) -
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.